Fusion Pharmaceuticals
phase trial preliminary safety summary | Fusion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
29 of 33
Similar slides by Fusion Pharmaceuticals
See diffirences between slides (animation)
Investor Presentation
November 2023
phase trial preliminary safety summary | Fusion Pharmaceuticals
Related slides by other companies
ATAI
Investor Presentation
September 2022
summary phase trial showed a rapid sustained reduction in depressive symptoms | ATAI
ATAI
Investor Presentation
November 2022
summary phase trial showed a rapid sustained reduction in depressive symptoms | ATAI
Bionomics
Results
March 2023
adverse event summary highly favorable safety profile | Bionomics
Larimar Therapeutics
Results
November 2022
safety in the mad study | Larimar Therapeutics
Other recent decks by Fusion Pharmaceuticals
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
November 2023
IPO
June 2020
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights